Quick Answer
Immuneering Corp reported Stockholders Equity of $218.48 million for fiscal year 2025.
Immuneering Corp Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $218.48M | +427.9% |
| 2024 | $41.39M | -54.3% |
| 2023 | $90.58M | -17.5% |
| 2022 | $109.85M | -29.6% |
| 2021 | $155.98M | +793.8% |
| 2020 | -$22.48M | -244.4% |
| 2019 | -$6.53M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $227.98M | +295.0% | +687.9% |
| June 30, 2025 | $28.94M | -56.4% | -30.8% |
| March 31, 2025 | $41.84M | -46.8% | +1.1% |
| December 31, 2024 | $41.39M | -54.3% | -28.3% |
| September 30, 2024 | $57.72M | -44.5% | -12.9% |
| June 30, 2024 | $66.31M | -42.4% | -15.8% |
| March 31, 2024 | $78.72M | -19.5% | -13.1% |
| December 31, 2023 | $90.58M | -17.5% | -12.9% |
- Immuneering Corp showed an increase of +427.9% in Stockholders Equity compared to the prior fiscal year.
- Over the 2019–2025 period, Immuneering Corp’s stockholders equity has grown by 3446.7% (from -$6.53 million to $218.48 million).
- The most recent figure is from Immuneering Corp’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 6, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: